You are receiving this email because you subscribed to 23andMe.
For information about our privacy practices, see our Privacy Statement.
*The 23andMe PGS test includes health predisposition and carrier status reports. Health predisposition
reports include both reports that meet US FDA requirements for genetic health risks and the 23andMe
Type 2 Diabetes health predisposition report which is based on 23andMe research and has not been
reviewed by the FDA. The test uses qualitative genotyping to detect select clinically relevant variants in
the genomic DNA of adults from saliva for the purpose of reporting and interpreting genetic health risks
and reporting carrier status. It is not intended to diagnose any disease. Your ethnicity may affect the
relevance of each report and how your genetic health risk results are interpreted. Each genetic health
risk report describes if a person has variants associated with a higher risk of developing a disease, but
does not describe a person’s overall risk of developing the disease. The test is not intended to tell you
anything about your current state of health, or to be used to make medical decisions, including whether
or not you should take a medication, how much of a medication you should take, or determine any
treatment. Our carrier status reports can be used to determine carrier status, but cannot determine if
you have two copies of any genetic variant. These carrier reports are not intended to tell you anything
about your risk for developing a disease in the future, the health of your fetus, or your newborn child’s
risk of developing a particular disease later in life. For certain conditions, we provide a single report that
includes information on both carrier status and genetic health risk. For important information and
limitations regarding each genetic health risk and carrier status report, visit 23andme.com/test-info/.
**23andMe PGS Pharmacogenetics reports: The 23andMe test uses qualitative genotyping to detect 3 variants in the CYP2C19 gene, 2 variants in the DPYD gene and 1 variant in the SLCO1B1 gene in the genomic DNA of adults from saliva for the purpose of reporting and interpreting information about the processing of certain therapeutics to inform discussions with a healthcare professional. It does not describe if a person will or will not respond to a particular therapeutic and does not describe the association between detected variants and any specific therapeutic. Our CYP2C19 Pharmacogenetics report provides certain information about variants associated with metabolism of some
therapeutics and provides interpretive drug information regarding the potential effect of citalopram and clopidogrel therapy. Results for SLCO1B1 and DPYD and certain CYP2C19 results should be confirmed by an independent genetic test prescribed by your own healthcare provider before taking any medical action. Warning:
Test information should not be used to start, stop, or change any course of treatment and does not test for all possible variants that may affect metabolism or protein function. The PGS test is not a substitute for visits to a healthcare professional. Making changes to your current regimen can lead to harmful side effects or reduced intended benefits of your medication, therefore consult with your healthcare professional before taking any medical action. For important information and limitations regarding Pharmacogenetic reports, visit
www.23andme.com/test-info/.
Discount will be applied to the first full priced service of higher value on 23andMe.com, placed after clicking in this email. Discount does not apply to applicable taxes or prior purchases. Cannot be combined with other offers or discounts. No adjustments on previous purchases. Offer is transferable to one person only and subject to change without notice.
Receive free standard shipping on your purchase at 23andMe.com. Offer is valid at 23andMe.com only and is not available on Amazon.com, FSA Store or HSA Store. Additional charges apply for all other shipping options and is only available in the U.S.
© 2007 - 2023 23andMe, Inc.
23andMe, Inc. 349 Oyster Point Blvd, South San Francisco, CA 94080, USA
Unsubscribe from 23andMe news and updates emails |
